The Challenges of Studying Peripheral Vestibular Vertigo

  • James G. NaplesEmail author
Letter to the Editor

Dear Editor,

I am writing in response to the recent article regarding the efficacy and safety of cinnarizine/dimenhydrinate versus betahistine in patients with peripheral vestibular vertigo by Scholtz et al. [1]. I would like to commend the authors and institutions for organizing and executing such a complicated study. In the otolaryngology literature, blinded, randomized trials are uncommon, as such, this work is an important step in acquiring sound methodological information. Additionally, I think there is reasonable molecular and basic science evidence to suggest there may be an important role for calcium as an ion that is essential in regulatory function of the vestibular system [2, 3]. Calcium-channel blockers (CCBs) were introduced as a possible therapy decades ago [4], and a combination therapy with CCBs is an important concept to build upon since it has not gained wide-spread use—at least in the USA. While the methodology and basic science are valid, there are always...


Compliance with Ethical Standards


No funding was received to prepare this letter.

Conflict of interest

The author declares no conflict of interest.


  1. 1.
    Scholtz AW, Hahn A, Stefflova B, et al. Efficacy and safety of a fixed combination of cinnarizine 20 mg and dimenhydrinate 40 mg vs betahistine dihydrochloride 16 mg in patients with peripheral vestibular vertigo: a prospective, multinational, multicenter, double-blind, randomized. Non-inferiority clinical trial. Clin Drug Investig. 2019;39(11):1045–56.CrossRefGoogle Scholar
  2. 2.
    Pangrsic T, Singer JH, Koschak A. Voltage-gated calcium channels: key players in sensory coding in the retina and the inner ear. Physiol Rev. 2018;98(4):2063–96.CrossRefGoogle Scholar
  3. 3.
    Castellano-Munoz M, Schnee ME, Ricci AJ. Calcium-induced calcium release supports recruitment of synaptic vesicles in auditory hair cells. J Neurophysiol. 2016;115(1):226–39.CrossRefGoogle Scholar
  4. 4.
    Lassen LF, Hirsch BE, Kamerer DB. Use of nimodipine in the medical treatment of Meniere’s disease: clinical experience. Am J Otol. 1996;17(4):577–80.PubMedGoogle Scholar
  5. 5.
    Scholtz AW, Ilgner J, Loader B, et al. Cinnarizine and dimenhydrinate in the treatment of vertigo in medical practice. Wien Klin Wochenschr. 2016;128(9–10):341–7.CrossRefGoogle Scholar
  6. 6.
    Scholtz AW, Steindl R, Burchardi N, et al. Comparison of the therapeutic efficacy of a fixed low-dose combination of cinnarizine and dimenhydrinate with betahistine in vestibular neuritis: a randomized, double-blind, non-inferiority study. Clin Drug Investig. 2012;32(6):387–99.CrossRefGoogle Scholar
  7. 7.
    Scholtz AW, Schwarz M, Baumann W, et al. Treatment of vertigo due to acute unilateral vestibular loss with a fixed combination of cinnarizine and dimenhydrinate: a double-blind, randomized, parallel-group clinical study. Clin Ther. 2004;26(6):866–77.CrossRefGoogle Scholar
  8. 8.
    Committee on Hearing and Equilibrium. Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Meniere’s disease. American Academy of Otolaryngology-Head and Neck Foundation, Inc. Otolaryngol Head Neck Surg. 1995;113(3):181–5.CrossRefGoogle Scholar
  9. 9.
    Lopez-Escamez JA, Carey J, Chung WH, et al. Diagnostic criteria for Meniere’s disease. J Vestib Res. 2015;25(1):1–7.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Otolaryngology-Head and Neck Surgery, Harvard Medical SchoolBeth Israel Deaconess Medical CenterBostonUSA

Personalised recommendations